The sole therapy accessible for individuals with leprechaunism thus far is recombinant IGF1, aiming to forestall compensatory hyperinsulinemia (23). IGF has about the 6% on the glucose-decreasing action outcome of insulin and it has the same construction to it, consequently it is able to bind to insulin receptors triggering peripheral glucose uptak